Improving outcome in the first-line management of advanced ovarian cancer

European Journal of Cancer, Supplement

Volumn 5, Issue 1, 2007, Pages 23-28

  Vergote, Ignace ^a   Van Gorp, Toon ^a   Cadron, Isabelle ^a   Leunen, Karin ^a   Neven, Patrick ^a   Amant, Frederic ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Advanced ovarian cancer; Biological agents; Carboplatin plus paclitaxel; Debulking surgery; First line therapy; Intraperitoneal chemotherapy; Maintenance chemotherapy

Indexed keywords

ANTHRACYCLINE; BEVACIZUMAB; CARBOPLATIN; CETUXIMAB; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; ENZASTAURIN; EPIRUBICIN; ERLOTINIB; GEFITINIB; GEMCITABINE; LAPATINIB; LONAFARNIB; PACLITAXEL; PERTUZUMAB; PLACEBO; PROTEIN TYROSINE KINASE INHIBITOR; RAF PROTEIN; TOPOTECAN; TRASTUZUMAB; VASCULOTROPIN INHIBITOR;

ABDOMINAL DISCOMFORT; ADVANCED CANCER; ARTICLE; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; DRUG DOSAGE FORM COMPARISON; FEBRILE NEUTROPENIA; HUMAN; MAINTENANCE THERAPY; MULTIPLE CYCLE TREATMENT; OVARY CANCER; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 34248559837     PISSN: 13596349     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6349(07)70012-5     Document Type: Article

References (24)

1. Ozols R. Treatment goals in ovarian cancer. Int J Gynecol Cancer 15 Suppl 1 (2005) 3-11
2. Thigpen T., Stuart G., du Bois A., et al. Clinical trials in ovarian carcinoma:requirements for standard approaches and regimens. Ann Oncol 16 Suppl 8 (2005) viii13-viii19
3. International Collaborative Ovarian Neoplasm Group. Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer:the ICON3 randomised trial. Lancet 360 (2002) 505-515
4. du Bois A., Weber B., Rochon J., et al. Addition of epirubicin as a third drug to carboplatin-paclitaxel in first-line treatment of advanced ovarian cancer: a prospectively randomized gynecologic cancer intergroup trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group and the Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens. J Clin Oncol 24 (2006) 1127-1135
5. Kristensen G., Vergote I., Stuart G., et al. First-line treatment of ovarian cancer FIGO stages IIb-IV with paclitaxel/epirubicin/carboplatin versus paclitaxel/carboplatin. Int J Gynecol Cancer 13 Suppl 2 (2003) 172-177
6. Bookman M., and for the Gynecologic Cancer InterGroup (GCIG). GOG0182-ICON5:5-arm phase III randomized trial of paclitaxel (P) and carboplatin (C) vs combinations with gemcitabine (G), PEG-lipososomal doxorubicin (D), or topotecan (T) in patients (pts) with advanced-stage epithelial ovarian (EOC) or primary peritoneal (PPC) carcinoma. J Clin Oncol 24 Suppl 18S (2006) [abstract 5002]
7. Hoskins P., Eisenhauer E., Vergote I., et al. Phase II feasibility study of sequential couplets of cisplatin/topotecan followed by paclitaxel/cisplatin as primary treatment for advanced epithelial ovarian cancer:a National Cancer Institute of Canada Clinical Trials Group Study. J Clin Oncol 18 (2000) 4038-4044
8. du Bois A., Sehouli J., Lund, et al. Paclitaxel-carboplatin-gemcitabine (TCG) as first-line treatment of ovarian cancer:a prospective multicenter phase II study (AGO-OVAR 8) followed by a prospectively randomized phase III GCIG Intergroup study (AGO-OVAR 9, GINECO-TCG, NSGO-OC-0102) comparing TCG with standard TC. Int J Gynecol Cancer 15 Suppl 3 (2005) 224-225
9. Vasey P., Jayson G., Gordon A., et al. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. J Natl Cancer Inst 96 (2004) 1682-1691
10. Armstrong D., Bundy B., Wenzel L., et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 354 (2006) 34-43
11. Alberts D., Liu P., Hannigan E., et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med 335 (1996) 1950-1955
12. Markman M., Bundy B., Alberts D., et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, South-western Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol 19 (2001) 1001-1007
13. Perez E. Paclitaxel in breast cancer. Oncologist 3 (1998) 373-389
14. Gore M., du Bois A., and Vergote I. Intraperitoneal chemotherapy in ovarian cancer remains experimental. J Clin Oncol 24 (2006) 4528-4530
15. Pfisterer J., Weber B., Reuss A., et al. Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer:a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO. J Natl Cancer Inst 98 (2006) 1036-1045
16. De Placido S., Scambia G., Di Vagno G., et al. Topotecan compared with no therapy after response to surgery and carboplatin/paclitaxel in patients with ovarian cancer: Multicenter Italian Trials in Ovarian Cancer (MITO-1) randomized study. J Clin Oncol 22 (2004) 2635-2642
17. Piccart M., Floquet A., Scarfone G., et al. Intraperi-toneal (IP) cisplatin (P) versus no further treatment:8 year results of an EORTC-GCG randomised phase III study in ovarian cancer (OC) patients (PTS) with a pathologically complete remission (PCR) after P-based induction chemotherapy (CT) and cytoreductive surgery. Int J Gynecol Cancer 13 Suppl 1 (2003) 8
18. Bolis G., Danese S., Tateo S., et al. Epidoxorubicin versus no treatment as consolidation therapy in advanced ovarian cancer:results from a phase II study. Int J Gynecol Cancer 16 Suppl 1 (2006) 74-78
19. Markman M., Liu P., Wilczynski S., et al. Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy:a Southwest Oncology Group and Gynecologic Oncology Group trial. J Clin Oncol 21 (2003) 2460-2465
20. Markman M., Liu P., Wilczynski S., Monk B., Copeland L., and Alberts D. Survival (S) of ovarian cancer (OC) patients (pts) treated on SWOG9701/GOG178:12 versus (v)3 cycles (C) of monthly single-agent paclitaxel (PAC) following attainment of a clinically-defined complete response (CR) to platinum (PLAT)/PAC. J Clin Oncol 24 Suppl 18S (2006) 5005
21. Aghajanian C. The role of bevacizumab in ovarian cancer-An evolving story. Gynecol Oncol 102 (2006) 131-133
22. Cannistra S., Matulonis U., Penson R., et al. Bevacizumab in patients with advanced platinum-resistant ovarian cancer. Proc Am Soc Clin Oncol 24 (2006) 257s [abstract 5006]
23. Burger R., Sill M., Monk B., Greer B., and Sorosky J. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer (EOC) or primary peritoneal cancer (PPC):a Gynecologic Oncology Group (GOG) study. J Clin Oncol 23 Suppl 16S (2005) [abstract 5009]
24. Graff J., McNulty A., Hanna K., et al. The protein kinase Cbeta-selective inhibitor, enzastaurin (LY317615. HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts. Cancer Res 65 (2005) 7462-7469